title: Value of bevacizumab in treatment of colorectal cancer: A meta-analysis.
abstract: OBJECTIVE
  To assess the efficacy and safety of bevacizumab in the treatment of colorectal cancer.
  
  
  METHODS
  All randomized controlled trials of bevacizumab for the treatment of colorectal cancer from January 2003 to June 2013 were collected by searching the Cochrane Library, PubMed, Chinese National Knowledge Infrastructure and Wanfang databases. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival, overall response rate and adverse events. Two reviewers extracted data independently. Statistical analyses were performed with Stata 12.0. The degree of bias was assessed using funnel plots for the effect size of OS at the primary endpoint.
  
  
  RESULTS
  Following the inclusion criteria and exclusion criteria, ten studies comprising 6977 cases were finally included, of which nine were considered to be of high quality (4-7 points) and one of low quality (1-3 points). Our meta-analysis revealed the efficacy of bevacizumab in patients with colorectal cancer in terms of OS (HR = 0.848, 95%CI: 0.747-0.963), progression-free survival (HR = 0.617, 95%CI: 0.530-0.719), and overall response rate (OR = 1.627, 95%CI: 1.199-2.207). Regarding safety, higher rates of grade ≥ 3 hypertension, proteinuria, bleeding, thrombosis, and gastrointestinal perforation were observed in the bevacizumab treatment group (P < 0.05); however, the incidence of serious toxicity was very low. There was no publication bias in the 10 reports included in this meta-analysis.
  
  
  CONCLUSIONS
  The clinical application of bevacizumab in colorectal cancer is effective with good safety.
authors.affiliation: Chun-Ying Qu, Min Zhou, Yi Zhang, Feng Shen, Jia Cao, Lei-Ming Xu, Department of Digestive Diseases, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
authors.forename: Chun-Ying
authors.initials: CY
authors.lastname: Qu
authors.affiliation: Chun-Ying Qu, Min Zhou, Yi Zhang, Feng Shen, Jia Cao, Lei-Ming Xu, Department of Digestive Diseases, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zheng
authors.affiliation: Chun-Ying Qu, Min Zhou, Yi Zhang, Feng Shen, Jia Cao, Lei-Ming Xu, Department of Digestive Diseases, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
authors.forename: Min
authors.initials: M
authors.lastname: Zhou
authors.affiliation: Chun-Ying Qu, Min Zhou, Yi Zhang, Feng Shen, Jia Cao, Lei-Ming Xu, Department of Digestive Diseases, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Chun-Ying Qu, Min Zhou, Yi Zhang, Feng Shen, Jia Cao, Lei-Ming Xu, Department of Digestive Diseases, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Shen
authors.affiliation: Chun-Ying Qu, Min Zhou, Yi Zhang, Feng Shen, Jia Cao, Lei-Ming Xu, Department of Digestive Diseases, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Cao
authors.affiliation: Chun-Ying Qu, Min Zhou, Yi Zhang, Feng Shen, Jia Cao, Lei-Ming Xu, Department of Digestive Diseases, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
authors.forename: Lei-Ming
authors.initials: LM
authors.lastname: Xu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Bevacizumab; Clinical application; Colorectal cancer; Meta-analysis; Randomized controlled trials